Tag: Biotech and Pharma

The stock of Hims & Hers dropped in premarket trading early Friday after a legal threat from Novo Nordisk.

Bristol Myers Squibb (BMY) rose Thursday on the back of better-than-expected fourth-quarter earnings but most encouraging was an upbeat outlook from the drugmaker.

GSK Plc reported better-than-expected profit in the fourth quarter, buoyed by its HIV and asthma medicines.

AbbVie forecast 2026 profit above Wall Street estimates on Wednesday after posting a fourth-quarter results beat, fueled by strong ​demand for newer immunology drugs Skyrizi and Rinvoq and a smaller-than-expected ‌decline in sales of its older medicine Humira.

Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise pre-released its 2026 forecast late Tuesday, sending shares tumbling.

Eli Lilly on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars.

Pfizer on Tuesday reported fourth-quarter results that topped estimates even amid dwindling demand for its Covid products, while reaffirming its modest 2026 guidance that rattled investors in December.

Merck & Co. (MRK) shares have dropped 1.6% premarket on Tuesday after the pharmaceutical giant issued 2026 guidance below analyst expectations, overshadowing solid fourth-quarter results that met earnings forecasts and slightly exceeded revenue estimates.

Shares of Abbott Laboratories (ABT) tumbled Thursday after the medical devices maker posted fourth-quarter earnings and sales that underwhelmed Wall Street.

Johnson & Johnson had another strong quarter, driven by revenue growth of two important cancer drugs, but it also reported lower-than-expected net profit.

Novo Nordisk (NVO) traded higher in the U.S. after the U.K.’s healthcare regulator approved a higher dose of Novo’s blockbuster weight-loss drug, Wegovy.

Walmart (WMT) stock rose 3.6% Monday morning after the retail giant was announced to join the Nasdaq-100 Index effective January 20, 2026.

Johnson & Johnson has said it will lower the price of some medications sold to U.S. consumers, making it the latest pharmaceutical company to form a business agreement with the Trump administration.

US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of more than $20bn in what would be the latest big deal in the red-hot biotechnology sector.

Novo Nordisk will start rolling out the first-ever GLP-1 pill for weight loss in the U.S. on Monday, the company announced, marking a new chapter of obesity treatment in the U.S.

Sanofi (SASY) will buy U.S. vaccines company Dynavax Technologies (DVAX) for around $2.2 billion (1.9 billion euros), the French drugmaker said on Wednesday, a deal that will give it access to an approved hepatitis B vaccine.

Novo Nordisk shares received a much-needed end of the year boost as the Wegovy maker became the first drugmaker to secure approval of a GLP-1 pill for weight loss, in what one analyst called a “redemption for the investors” after the stock’s worst year ever.

Eli Lilly on Thursday said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking the company’s injection Zepbound and Novo Nordisk’s rival shot Wegovy in a late-stage trial.

Pfizer (PFE), on Tuesday forecast 2026 profit below Wall Street estimates as it expects a steep drop in sales of its COVID products and a revenue hit from the loss of exclusivity on some drugs.

Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t be completed by the end of the year and that a trial for a different form of MS didn’t succeed.